newsfilter
← Latest News
GlobeNewswire·

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD